Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies

Luca Degli Esposti,1 Valentina Perrone,1 Diego Sangiorgi,1 Stefano Buda,1 Margherita Andretta,2 Maurizio Rossini,3 Giampiero Girolomoni4 1CliCon Srl, Health Economics and Outcomes Research, Ravenna, Italy; 2Pharmaceutical Department Local Health Unit, ULSS 9 Scaligera, Verona, Italy; 3Department of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Degli Esposti L, Perrone V, Sangiorgi D, Buda S, Andretta M, Rossini M, Girolomoni G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	psoriasis psoriatic arthritis biological treatment healthcare costs hospitalization Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/5a5b2625cab1418889b0089faf435c7b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5a5b2625cab1418889b0089faf435c7b
record_format	dspace
spelling	oai:doaj.org-article:5a5b2625cab1418889b0089faf435c7b2021-12-02T06:03:24ZAnalysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies1177-5491https://doaj.org/article/5a5b2625cab1418889b0089faf435c7b2018-11-01T00:00:00Zhttps://www.dovepress.com/analysis-of-drug-utilization-and-health-care-resource-consumption-in-p-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Luca Degli Esposti,1 Valentina Perrone,1 Diego Sangiorgi,1 Stefano Buda,1 Margherita Andretta,2 Maurizio Rossini,3 Giampiero Girolomoni4 1CliCon Srl, Health Economics and Outcomes Research, Ravenna, Italy; 2Pharmaceutical Department Local Health Unit, ULSS 9 Scaligera, Verona, Italy; 3Department of Medicine, Section of Rheumatology, University of Verona, Verona, Italy; 4Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy Objectives: To describe the therapeutic pathways of patients with psoriasis (PSO) and psoriatic arthritis (PsA) before and after treatment with biological therapies in a real-world setting and to determine the relative consumption of health care resources.Design: Retrospective observational study.Setting: Real-life clinical setting in 5 Italian local health units.Participants: A total of 351 male and female patients with at least 1 prescription for a biological drug from January 1, 2010 to December 31, 2013; patients with concomitant rheumatoid arthritis, ankylosing spondylitis, or Crohn’s disease were excluded.Results: The major health care cost (excluding drug costs) was represented by hospitalizations, mainly related to PSO /PsA-associated disorders and cardiometabolic disorders. Use of conventional drugs among biologics-naïve patients reached 50% in PSO and 80% in PsA; their use decreased following initiation of biological therapy. After the start of biological treatment, the incidence of hospitalization decreased both for PSO (from 12.3% to 3.2% in day hospital regimen and from 2.4% to 0.4% for conventional admission) and for PsA (from 11.1% to 8.1% and from 10.1% to 3.0%, respectively). Mean annual costs for hospitalization before biological treatment were €217 and €537 for PSO and PsA, respectively, while mean annual cost for concomitant drugs slightly increased after biologics initiation: from €249.8 to €269.4 for PSO and from €331.8 to €346.9 for PsA. The major consumption of health care resources occurred in the quarter preceding the beginning of biological treatment.Conclusion: The consumption of health resources is mostly related to hospitalization, seems to peak during the quarter before the beginning of biologics therapies, and subsequently decreases after biologics initiation. Further studies should focus on prescription scheme and economic burden of PSO and PsA in Italy to help optimize health care resources and potentiate services for patients. Keywords: psoriasis, psoriatic arthritis, biological treatment, health care costs, hospitalizationDegli Esposti LPerrone VSangiorgi DBuda SAndretta MRossini MGirolomoni GDove Medical Pressarticlepsoriasispsoriatic arthritisbiological treatmenthealthcare costshospitalizationMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 12, Pp 151-158 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	psoriasis psoriatic arthritis biological treatment healthcare costs hospitalization Medicine (General) R5-920
spellingShingle	psoriasis psoriatic arthritis biological treatment healthcare costs hospitalization Medicine (General) R5-920 Degli Esposti L Perrone V Sangiorgi D Buda S Andretta M Rossini M Girolomoni G Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies
description	Luca Degli Esposti,1 Valentina Perrone,1 Diego Sangiorgi,1 Stefano Buda,1 Margherita Andretta,2 Maurizio Rossini,3 Giampiero Girolomoni4 1CliCon Srl, Health Economics and Outcomes Research, Ravenna, Italy; 2Pharmaceutical Department Local Health Unit, ULSS 9 Scaligera, Verona, Italy; 3Department of Medicine, Section of Rheumatology, University of Verona, Verona, Italy; 4Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy Objectives: To describe the therapeutic pathways of patients with psoriasis (PSO) and psoriatic arthritis (PsA) before and after treatment with biological therapies in a real-world setting and to determine the relative consumption of health care resources.Design: Retrospective observational study.Setting: Real-life clinical setting in 5 Italian local health units.Participants: A total of 351 male and female patients with at least 1 prescription for a biological drug from January 1, 2010 to December 31, 2013; patients with concomitant rheumatoid arthritis, ankylosing spondylitis, or Crohn’s disease were excluded.Results: The major health care cost (excluding drug costs) was represented by hospitalizations, mainly related to PSO /PsA-associated disorders and cardiometabolic disorders. Use of conventional drugs among biologics-naïve patients reached 50% in PSO and 80% in PsA; their use decreased following initiation of biological therapy. After the start of biological treatment, the incidence of hospitalization decreased both for PSO (from 12.3% to 3.2% in day hospital regimen and from 2.4% to 0.4% for conventional admission) and for PsA (from 11.1% to 8.1% and from 10.1% to 3.0%, respectively). Mean annual costs for hospitalization before biological treatment were €217 and €537 for PSO and PsA, respectively, while mean annual cost for concomitant drugs slightly increased after biologics initiation: from €249.8 to €269.4 for PSO and from €331.8 to €346.9 for PsA. The major consumption of health care resources occurred in the quarter preceding the beginning of biological treatment.Conclusion: The consumption of health resources is mostly related to hospitalization, seems to peak during the quarter before the beginning of biologics therapies, and subsequently decreases after biologics initiation. Further studies should focus on prescription scheme and economic burden of PSO and PsA in Italy to help optimize health care resources and potentiate services for patients. Keywords: psoriasis, psoriatic arthritis, biological treatment, health care costs, hospitalization
format	article
author	Degli Esposti L Perrone V Sangiorgi D Buda S Andretta M Rossini M Girolomoni G
author_facet	Degli Esposti L Perrone V Sangiorgi D Buda S Andretta M Rossini M Girolomoni G
author_sort	Degli Esposti L
title	Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies
title_short	Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies
title_full	Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies
title_fullStr	Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies
title_full_unstemmed	Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies
title_sort	analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/5a5b2625cab1418889b0089faf435c7b
work_keys_str_mv	AT degliespostil analysisofdrugutilizationandhealthcareresourceconsumptioninpatientswithpsoriasisandpsoriaticarthritisbeforeandaftertreatmentwithbiologicaltherapies AT perronev analysisofdrugutilizationandhealthcareresourceconsumptioninpatientswithpsoriasisandpsoriaticarthritisbeforeandaftertreatmentwithbiologicaltherapies AT sangiorgid analysisofdrugutilizationandhealthcareresourceconsumptioninpatientswithpsoriasisandpsoriaticarthritisbeforeandaftertreatmentwithbiologicaltherapies AT budas analysisofdrugutilizationandhealthcareresourceconsumptioninpatientswithpsoriasisandpsoriaticarthritisbeforeandaftertreatmentwithbiologicaltherapies AT andrettam analysisofdrugutilizationandhealthcareresourceconsumptioninpatientswithpsoriasisandpsoriaticarthritisbeforeandaftertreatmentwithbiologicaltherapies AT rossinim analysisofdrugutilizationandhealthcareresourceconsumptioninpatientswithpsoriasisandpsoriaticarthritisbeforeandaftertreatmentwithbiologicaltherapies AT girolomonig analysisofdrugutilizationandhealthcareresourceconsumptioninpatientswithpsoriasisandpsoriaticarthritisbeforeandaftertreatmentwithbiologicaltherapies
_version_	1718400111934963712

Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies

Ejemplares similares